Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
390
-
Total 13F shares, excl. options
-
90.2M
-
Shares change
-
-976K
-
Total reported value, excl. options
-
$8.66B
-
Value change
-
-$94.9M
-
Put/Call ratio
-
0.58
-
Number of buys
-
165
-
Number of sells
-
-197
-
Price
-
$95.91
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q3 2021
457 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q3 2021.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 390 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.2M shares
of 99.6M outstanding shares and own 90.6% of the company stock.
Largest 10 shareholders include BlackRock Inc. (10.2M shares), JANUS HENDERSON GROUP PLC (8.99M shares), VANGUARD GROUP INC (8.89M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.46M shares), FMR LLC (3.47M shares), STATE STREET CORP (3.46M shares), Bellevue Group AG (3M shares), JPMORGAN CHASE & CO (2.69M shares), Bank of New York Mellon Corp (1.9M shares), and EATON VANCE MANAGEMENT (1.89M shares).
This table shows the top 390 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.